Compare Becton Dickinson and Co (BDX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Vertiv Holdings Co — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Vertiv Holdings Co trades at $305.98 (market cap $116.61B). The key difference: Vertiv Holdings Co is far larger — about 2.8× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | VRT | |
|---|---|---|
Market Cap | $41.51B | $116.61B |
Sector | Health | Technology |
52-Week High | $185.39 | $376.23 |
52-Week Low | $135.49 | $121.82 |
Enterprise Value | $57.97B | $117.37B |
Dividend Yield | 2.79% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Vertiv Holdings (VRT) trades at $305.87, down 4.07% today, amid strong fundamental performance with consistent earnings beats and robust AI-driven demand. The stock shows neutral technical signals with support at $300 and resistance at $314, while maintaining impressive profitability metrics including 45.1% ROE and 14.37% net margin. Recent news highlights Vertiv's $15 billion order backlog and expansion in Malaysia to capitalize on AI infrastructure growth.
The outlook remains positive with 94.7% analyst buy ratings and a $407.45 consensus target, representing 33% upside potential. Key risks include premium valuation multiples (P/E 76.28) and competitive pressures, but strong cash flow generation and AI infrastructure tailwinds support continued growth momentum through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
